Search for a clinical trial
Other search option(s)
6 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
AUSTRIA
WIEN
WIEN
ENHANCE: Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
SPAIN
Cataluña
BARCELONA
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure - ES
Hospital Universitari Vall d'Hebron
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE: Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Completed) - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure - ES
Hospital Universitario 12 de Octubre
SPAIN
Madrid
MADRID
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure - ES
Hospital Universitario Ramón y Cajal
Multinational clinical trial(s)
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US